# Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy

> **NCT02317393** · PHASE2 · COMPLETED · sponsor: **Centre Francois Baclesse** · enrollment: 16 (actual)

## Conditions studied

- Non-seminomatous Germ Cell Tumors
- Metastasis

## Interventions

- **OTHER:** K5-RGD PET
- **OTHER:** FDG

## Key facts

- **NCT ID:** NCT02317393
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02317393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02317393, "Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02317393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*